- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01184872
Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections
An Open Label, Multi-center, Randomized, Comparative Phase IIIb Study to Compare Efficacy and Safety of Intravenous (i.v.) Daptomycin With That of Semi-Synthetic Penicillins (SSPs) or Vancomycin in the Treatment of Elderly Patients (Aged ≥ 65 Years) With Complicated Skin and Soft Tissue Infections (cSSTI)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Graz, Austria
- Novartis Investigative Site
-
Vienna, Austria
- Novartis Investigative Site
-
-
-
-
-
Bochum, Germany
- Novartis Investigative Site
-
Essen, Germany
- Novartis Investigative Site
-
Homburg, Germany
- Novartis Investigative Site
-
Magdeburg, Germany
- Novartis Investigative Site
-
Mannheim, Germany
- Novartis Investigative Site
-
Muenster, Germany
- Novartis Investigative Site
-
Tuebingen, Germany
- Novartis Investigative Site
-
-
-
-
-
Pisa, Italy
- Novartis Investigative Site
-
-
-
-
-
Moscow, Russian Federation
- Novartis Investigative Site (1)
-
Novosibirsk, Russian Federation
- Novartis Investigative Site
-
Saint Petersburg, Russian Federation
- Novartis Investigative Site (2)
-
Yaroslavi, Russian Federation
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spain
- Novartis Investigative Site (1)
-
Santander, Spain
- Novartis Investigative Site
-
Seville, Spain
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Patients 65 years or older with infection of sufficient severity to require in-patient hospitalization, with parenteral antimicrobial therapy for at least 96 hours.
Patients who have a diagnosis of Gram-positive complicated Skin and Soft Tissue Infections (cSSTIs) with or without bacteremia:
- Wound infections,
- Major abscesses with or without recognized preceding trauma, that require antibiotic therapy in addition to surgical incision and drainage,
- Severe carbunculosis,
- Infected ulcers (except patients with multiple infected ulcers) associated with: diabetes, vascular insufficiency, pressure (i.e., decubitus ulcers).
Exclusion criteria:
Conditions requiring surgery that in and of itself would cure the infection or remove the infected site (e.g., amputation).
Minor or superficial skin infections (e.g., furuncles, simple abscesses, acne, impetigo).
Cellulitis, including erysipelas, not associated with complicating factors. However, patients with cellulitis associated with more serious infection (e.g., surgical wound, diabetic ulcer, deep tissue) can be enrolled (proportion of these patients will be limited to 30%).
Infections for which outcome is difficult to assess:
- Perirectal abscess,
- Hidradenitis suppurativa,
- Gangrene,
- Infected human or animal bites,
- Multiple infected ulcers at distant sites,
- Infected burns (only third degree burn wound or wound area of more than 10 cm diameter),
- Conditions requiring emergency surgery including necrotizing fasciitis.
Medical conditions:
- History of significant allergy or intolerance to Vancomycin or Daptomycin. Hypersensitivity to SSPs penicillins is not an exclusion criterion,
- Concomitant clinically suspected or confirmed other site of infection or disorder at study entry that may interfere with the evaluation in this protocol,
- Infections associated with a permanent prosthetic device that will not be removed within 24 hours after enrolment,
- Known or suspected HIV infection with a CD4+ T-cell count < 500/μL (HIV testing is not required),
- Severe hepatic disease (Child-Pugh Class C) or ALT and/or AST > 5 times ULN and/ or total bilirubin > 2 times ULN at screening,
- Calculated creatinine clearance by the Cockcroft-Gault equation using actual body weight < 30 mL/min or any type of dialysis,
- Treatment with any investigational agent or device within 30 days of study drug administration.
Exclusion criteria related to medications:
- Previous systemic antibacterial therapy for the treatment of Gram-positive complicated skin and soft tissue infections for more than 24 hours within 48 hours prior to the day of first infusion of study drug unless:
- The previous antibacterial therapy was administered for 3 or more calendar days with either worsening or no improvement in the clinical signs and symptoms of cSSTIs, and was not Vancomycin or SSPs.
Other protocol-defined inclusion/exclusion criteria applied.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Daptomycin
Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days. Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days. |
Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days. Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days. |
ACTIVE_COMPARATOR: Vancomycin or Semi-Synthetic Penicillins (SSPs)
Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days. Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days. |
Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days. Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Clinical Success at the Test-Of-Cure (TOC) Visit
Time Frame: Baseline and 7 to 14 days after end of therapy
|
Success: Clinically significant signs and symptoms associated with the skin infection present at the pre-treatment infection site resolved (cure), or improved without need of further antibacterial therapy.
Failure: Persistence or progression of signs and symptoms or development of new clinical signs and symptoms at the infection site, or concomitant antibacterial therapy with activity against isolated organisms, or treatment duration longer than pre-specified, or switch back to intravenous therapy due to relapse, or requirement of a major surgical procedure as adjunct or follow-up therapy.
|
Baseline and 7 to 14 days after end of therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Microbiological Response at Test-of-Cure (TOC) Visit
Time Frame: Baseline and 7 to 14 days after end of therapy
|
Microbiological Success: All infecting Gram-positive pathogens isolated at baseline were eradicated or presumed to be eradicated at the Test-of-Cure (TOC) evaluation and a super infecting pathogen was not isolated either prior to or at the TOC evaluation.
Microbiological Failure: Persistence or relapse / re-infection of one or more infecting Gram-positive pathogens or isolation of a super infecting pathogen prior to or at the TOC evaluation.
|
Baseline and 7 to 14 days after end of therapy
|
Duration of Treatment (Intravenous)
Time Frame: Up to 28 days
|
Duration of treatment is the interval from first to last intravenous (i.v.) administration.
It was preferable that a patient complete the whole antibiotic treatment with the randomized i.v.
study drug only.
Duration of treatment in patients with bacteremia could be extended up to 28 days.
|
Up to 28 days
|
Duration of Treatment (Intravenous and Oral)
Time Frame: Up to 28 days
|
Duration of treatment is the interval from first to last intravenous (i.v.) or to last oral administration if patients switched to an oral antibiotic therapy.
It was preferable that a patient complete the whole antibiotic treatment with the randomized i.v.
study drug only.
Duration of treatment in patients with bacteremia could be extended up to 28 days.
|
Up to 28 days
|
Number of Patients With Adverse Events, Serious Adverse Events and Death
Time Frame: Continuously from baseline up to 28 days after end of antibiotic treatment.
|
Continuously from baseline up to 28 days after end of antibiotic treatment.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCBC134A2404
- 2009-014391-22 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
MJM BontenJanssen Research & Development, LLC; Innovative Medicines InitiativeCompletedE.Coli InfectionsUnited States, United Kingdom, Canada, France, Germany, Italy, Japan, Spain
-
University of PittsburghWithdrawn
-
PfizerCompletedGroup B Streptococcus InfectionsUnited States, South Africa, United Kingdom
-
GlaxoSmithKlineActive, not recruitingInfections, MeningococcalFinland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
-
PfizerCompletedInfections, MeningococcalAustralia, Canada, Czechia, Panama, South Africa, Turkey
-
GlaxoSmithKlineCompletedInfections, MeningococcalFinland
-
PfizerCompletedInfections, MeningococcalPhilippines
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States, Finland, Poland
Clinical Trials on Daptomycin
-
Cubist Pharmaceuticals LLCTerminatedWound Infections
-
Cubist Pharmaceuticals LLCCompletedGram Positive Infection | Concurrent Antibiotic TreatmentUnited States
-
Cubist Pharmaceuticals LLCCompletedBacteremia | Bacterial Endocarditis
-
University Hospital, CaenCompletedPeritoneal InfectionFrance
-
Merck Sharp & Dohme LLCCompleted
-
Cubist Pharmaceuticals LLCTerminatedGram-Positive Bacterial Infections
-
University of Maryland, BaltimoreCubist Pharmaceuticals LLCCompletedFasciitis, Necrotizing | Fournier's Gangrene | Severe Necrotizing Skin and Soft Tissue InfectionsUnited States
-
Cubist Pharmaceuticals LLCCompletedGram-positive Bacterial InfectionsUnited States
-
Cubist Pharmaceuticals LLCCompleted
-
Cubist Pharmaceuticals LLCCompleted